Evidence map›Paper›PMID 41171441›Full record

ReviewHepatology communications2025

Chemoprevention of hepatocellular carcinoma.

Sara Schwenk, David E Kaplan

Abstract readReview
In one paragraph

Review in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sara SchwenkDepartment of Medicine, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-6818-9546
David E KaplanDepartment of Medicine, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-3839-336

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and a leading cause of cancer-related deaths globally. Chronic liver disease (CLD), primarily due to viral hepatitis, alcohol use, and metabolic dysfunction-associated steatotic liver disease with steatohepatitis (MASLD/MASH), remains the major risk factor for HCC development. Chemoprevention, the use of medications or supplements to prevent or delay cancer, offers a compelling strategy to reduce HCC incidence, especially during the extended latency period between CLD onset and HCC progression. This review evaluates the current evidence for chemopreventive strategies for HCC, including immunizations, pharmacologic therapies, and dietary supplements.

Indexed as

Carcinoma, HepatocellularChemopreventionLiver NeoplasmsDietary SupplementsHumansRisk FactorsantiviralsaspirincancererlotinibGLP1RAhumanstatins

Identifiers

PMID41171441
PMCPMC12577995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.